ARQT vs. SMMT
ARQT (Arcutis Biotherapeutics, Inc.) and SMMT (Summit Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ARQT returned -0.16%/yr vs 17.16%/yr for SMMT. At a 0.25 correlation, their price movements are largely independent.
Performance
ARQT vs. SMMT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARQT achieves a -8.20% return, which is significantly higher than SMMT's -18.35% return.
ARQT
- 1D
- 1.72%
- 1M
- 27.80%
- YTD
- -8.20%
- 6M
- -10.84%
- 1Y
- 92.91%
- 3Y*
- 44.81%
- 5Y*
- -0.16%
- 10Y*
- —
SMMT
- 1D
- 3.85%
- 1M
- -14.08%
- YTD
- -18.35%
- 6M
- -21.32%
- 1Y
- -30.54%
- 3Y*
- 75.32%
- 5Y*
- 17.16%
- 10Y*
- 5.97%
ARQT vs. SMMT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeutics, Inc. | -8.20% | 108.47% | 331.27% | -78.18% | -28.64% | -26.27% | 22.04% |
SMMT Summit Therapeutics Inc. | -18.35% | -1.99% | 583.72% | -38.59% | 57.99% | -42.77% | 224.14% |
Correlation
The correlation between ARQT and SMMT is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Jan 31, 2020 | 0.25 |
Fundamentals
ARQT:
$3.45B
SMMT:
$11.07B
ARQT:
-$0.02
SMMT:
-$1.60
ARQT:
18.19
SMMT:
20.28
ARQT:
$415.62M
SMMT:
$0.00
ARQT:
$377.98M
SMMT:
-$83.36K
ARQT:
$12.21M
SMMT:
-$738.34M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARQT vs. SMMT — Risk / Return Rank
ARQT
SMMT
ARQT vs. SMMT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARQT | SMMT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.02 | ||
| Sortino ratioReturn per unit of downside risk | +2.53 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 0.98 | +0.31 |
| Calmar ratioReturn relative to maximum drawdown | 2.49 | -0.55 | +3.04 |
| Martin ratioReturn relative to average drawdown | 5.68 | -0.86 | +6.53 |
Loading charts...
Drawdowns
ARQT vs. SMMT - Drawdown Comparison
The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum SMMT drawdown of -95.75%. Use the drawdown chart below to compare losses from any high point for ARQT and SMMT.
Loading charts...
Drawdown Indicators
| ARQT | SMMT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.02% | -95.75% | +0.73% |
Max Drawdown (1Y)Largest decline over 1 year | -37.50% | -55.49% | +17.99% |
Max Drawdown (3Y)Largest decline over 3 years | -83.24% | -64.44% | -18.80% |
Max Drawdown (5Y)Largest decline over 5 years | -93.28% | -91.78% | -1.50% |
Max Drawdown (10Y)Largest decline over 10 years | — | -95.75% | — |
Current DrawdownCurrent decline from peak | -27.91% | -61.09% | +33.18% |
Average DrawdownAverage peak-to-trough decline | -50.01% | -57.63% | +7.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.43% | 35.70% | -19.27% |
Volatility
ARQT vs. SMMT - Volatility Comparison
The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 10.98%, while Summit Therapeutics Inc. (SMMT) has a volatility of 19.19%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than SMMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARQT | SMMT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.98% | 19.19% | -8.21% |
Volatility (6M)Calculated over the trailing 6-month period | 37.84% | 56.82% | -18.98% |
Volatility (1Y)Calculated over the trailing 1-year period | 58.08% | 75.80% | -17.72% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 71.90% | 185.23% | -113.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 76.82% | 144.54% | -67.72% |
Dividends
ARQT vs. SMMT - Dividend Comparison
Neither ARQT nor SMMT has paid dividends to shareholders.
Financials
ARQT vs. SMMT - Financials Comparison
This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and Summit Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ARQT and SMMT have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SMMT has higher volatility (19.19%) compared to ARQT (10.98%). In terms of maximum drawdown, ARQT dropped -95.02% vs SMMT's -95.75%.
ARQT currently has the higher Sharpe Ratio (1.61 vs -0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARQT and SMMT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer